You are here: Industry Insights > Insys

News List

Insys agrees to sell notorious fentanyl spray to drugmaker promising good behavior fiercepharma
September 26, 2019
A Delaware bankruptcy judge cleared the sale of the highly addictive, under-the-tongue fentanyl spray Subsys to Wyoming-based BTcP Pharma LLC, part of the MMB Healthcare network. The deal could net Insys $20 million in royalties.
Hikma picks up Insys naloxone spray, equipment in $12M bankruptcy buy fiercepharma
August 22, 2019
The carcass of pain drug wheeler-dealer Insys Therapeutics is being pieced off in bankruptcy court, and Hikma Pharmaceuticals says it has picked up some of those pieces.
Struggling Insys swaps CEOs as Subsys marketing crackdown continues fiercepharma
April 18, 2019
Insys has weathered years of litigation, investigations and allegations of illegal sales practices to pump up powerful ……
Former Insys sales exec to shell out $9.5M in opioid spray kickback scheme fiercepharma
April 04, 2019
Insys’ former VP of sales has settled and turned state's evidence in an Arizona kickback suit alleging an executive-driven scheme to buy scripts for the company’s powerful opioid spray, Subsys.
Insys opioid reps rapped about boosting scripts by putting docs on the gravy train fiercepharma
February 24, 2019
An up-tempo rap about boosting prescriptions wouldn’t seem out of place at your average pharmaceutical sales meeting. But the video federal prosecutors played Wednesday in the racketeering trial of Insys founder John Kapoor, which focused on the company’s
Insys Therapeutics reaches $150m agreement to settle opioid marketing case pharmafile
August 10, 2018
The Arizona-based pharma company Insys Therapeutics has reached an agreement to pay $150 million to the US Department of Justice in order to settle criminal and civil investigations into inappropriate sales and commercial practices by former company emplo
Insys to cough up $150M to settle Justice Department's probe into Subsys sales fiercepharma
August 09, 2018
Insys Therapeutics may soon turn the page on the high-profile federal probe into its Subsys sales practices—a probe that has already snared a half-dozen former Insys managers now facing criminal charges.
INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray drugs
June 12, 2018
INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed today that an expert panel convened by the U.S. Food and Drug Administration (FDA) voted
INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray drugs
May 31, 2018
INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed today that an expert panel convened by the U.S. Food and Drug Administration
North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray biospace
December 25, 2017
North Carolina sued Insys on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic. The lawsuit announced by North Carolina Attorne